Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial

Abstract

ObjectiveMultifactorial intervention including the management of levels of blood glucose (BG), blood pressure (BP), and lipids has been suggested to decrease cardiovascular disease (CVD) risk. However, the target ideal and feasible levels for these individual parameters have not been fully evaluated. In this study, we examine the hypothesis that stricter control compared with the current targets in the Japanese guideline for BG, BP, and lipids could efficiently and safely reduce CVD risk.Research Design and MethodsWe screened patients with type 2 diabetes and hypertension and/or dyslipidemia among 81 hospitals in Japan and allocated them into 2 groups: the intensive therapy group (ITG) and the conventional therapy group (CTG). For the 2 respective groups, the target for glycated hemoglobin (HbA1c) is <6.2% (44 mmol/mol) and <6.9% (52 mmol/mol), for BP it is <120/75 mm Hg and <130/80 mm Hg, and for low-density lipoprotein cholesterol it is <80 mg/dL (<70 mg/dL in the presence of CVD history) and <120 mg/dL (<100 mg/dL in the presence of CVD history). The primary end point is the occurrence of CVD events or death by any cause. These patients are scheduled for stepwise intensifications of medication for BG, BP, and lipid control in the ITG, until the number of primary end point events reaches 250.ResultsWe recruited 2542 patients and randomly allocated 1271 into the ITG and 1271 into the CTG between June 2006 and March 2009. The mean HbA1c was 8.0% (64 mmol/mol) and the mean duration of diabetes was 8.3 years.ConclusionsThis randomized controlled study will test the hypothesis that strict multifactorial intervention therapy is effective for the prevention of CVDs in patients with type 2 diabetes who are at high CVD risk.Trial registration numberNCT00300976.

ASCVD risk stratification modifies the effect of HbA1c on cardiovascular events among patients with type 2 diabetes mellitus with basic to moderate risk

“…The accurate assessment of individual risk can be of great value to guiding and facilitating the prevention of ASCVD 21. As early as in 1976, the Framingham Heart Study identified several risk factors and developed the first coronary heart disease risk equations 22.…”

Effect of antihyperglycemic drug monotherapy to prevent the progression of mild hyperglycemia in early type 2 diabetic patients: the Japan Early Diabetes Intervention Study (JEDIS)

“…In Japan, three large-scale clinical trials supported by the Ministry of Health, Labor and Welfare are underway, i.e., Diabetes Outcome Intervention Trial (DOIT)-1, 2 and 3, the underlying rationales of which are the primary, secondary and tertiary preventions of T2DM [29,30]. This study, Japan Early Diabetes Intervention Study (JEDIS), complements these DOITs by comparing the effect on hyperglycemia of standard education and care for diabetes, i.e., lifestyle interventions, to that of additional administration of AHAs in patients with T2DM at its early stage without any complication.…”

Low Protein Brown Rice for Preventing Progression of CKD and DKD to End Stage Renal Failure

“…In Japan, J-Doit-3 study, in which 2,542 patients were randomly assigned either to ordinary therapy or intensive therapy with multiple targeting of HbA1c, blood pressure, LDL cholesterol, HDL cholesterol, triacylglycerol, and BMI purposed to suppress these values within the normal range. 6 A primary outcome occurred in 109 patients in the intensive therapy group and in 133 patients in the conventional therapy group (hazard ratio [HR] 0.81, p=0.094). Only cerebrovascular events were significantly less frequent in the intensive therapy group (HR 0.42, p=0.02), but hypoglycemia occurred in 41.1% patients in the intensive treatment vs. 22.3% in the control group.…”